FAQ: Kairos Pharma Ltd. Participation in D. Boral Capital Global Conference and Overview
Summary
Kairos Pharma Ltd. (NYSE American: KAPA) will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, showcasing its innovative oncology therapeutics, including its lead candidate ENV105, aimed at overcoming drug resistance in cancer treatments.
What is the main topic of the announcement?
The announcement highlights Kairos Pharma Ltd.’s participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, where it will discuss its oncology therapeutics, including the ENV105 antibody targeting CD105 to overcome drug resistance in cancer treatments.
Why is Kairos Pharma’s participation in the conference significant?
Kairos Pharma’s participation is significant because it provides an opportunity to showcase its innovative approach to overcoming drug resistance in cancer treatments, potentially attracting investors and partners interested in advancing oncology therapeutics.
How does ENV105 work in cancer treatment?
ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Who will represent Kairos Pharma at the conference?
CEO and Chairman John Yu, MD, will represent Kairos Pharma at the conference, hosting one-on-one meetings with investors from 9 a.m. to 3 p.m. ET.
When and where is the D. Boral Capital Global Conference taking place?
The conference is scheduled for May 14, 2025, at The Plaza Hotel in New York City.
What are the current clinical trials for ENV105?
ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in these areas.
Where can I find more information about Kairos Pharma Ltd.?
More information about Kairos Pharma Ltd. can be found on the company’s website at www.KairosPharma.com or in the company’s newsroom at https://ibn.fm/KAPA.
What is BioMedWire’s role in this announcement?
BioMedWire is a specialized communications platform that focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing a platform for companies like Kairos Pharma Ltd. to share their news and updates.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 116879